Latest & greatest articles for heparin

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on heparin or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on heparin and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for heparin

181. Subcutaneous heparin is as good as low-molecular-weight heparin in the acute treatment of thrombo-embolic disease

Subcutaneous heparin is as good as low-molecular-weight heparin in the acute treatment of thrombo-embolic disease BestBets: Subcutaneous heparin is as good as low-molecular-weight heparin in the acute treatment of thrombo-embolic disease Subcutaneous heparin is as good as low-molecular-weight heparin in the acute treatment of thrombo-embolic disease Report By: Andrew Munro - Staff Specialist Search checked by Cain English - Emergency Registrar Institution: Coffs Harbour Base Hospital Date (...) Submitted: 4th September 2007 Date Completed: 8th May 2008 Last Modified: 5th November 2007 Status: Green (complete) Three Part Question In [patients with DVT] is [subcutaneous unfractionated heparin as efficacious as low-molecular-weight heparin] in the [prevention of thrombo-embolic sequelae]? Clinical Scenario An Emergency Department Registrar presented a paper at our journal club showing the efficaciousness and cost effectiveness of home treatment with unfractionated heparin (UFH) in comparison

BestBETS2008

182. Contaminated Heparin Associated with Adverse Clinical Events and Activation of the Contact System.

Contaminated Heparin Associated with Adverse Clinical Events and Activation of the Contact System. BACKGROUND: There is an urgent need to determine whether oversulfated chondroitin sulfate (OSCS), a compound contaminating heparin supplies worldwide, is the cause of the severe anaphylactoid reactions that have occurred after intravenous heparin administration in the United States and Germany. METHODS: Heparin procured from the Food and Drug Administration, consisting of suspect lots of heparin (...) associated with the clinical events as well as control lots of heparin, were screened in a blinded fashion both for the presence of OSCS and for any biologic activity that could potentially link the contaminant to the observed clinical adverse events. In vitro assays for the activation of the contact system and the complement cascade were performed. In addition, the ability of OSCS to recapitulate key clinical manifestations in vivo was tested in swine. RESULTS: The OSCS found in contaminated lots

NEJM2008 Full Text: Link to full Text with Trip Pro

183. Unfractionated or low-molecular weight heparin for induction of remission in ulcerative colitis.

Unfractionated or low-molecular weight heparin for induction of remission in ulcerative colitis. BACKGROUND: There are a limited number of treatment options for patients with ulcerative colitis (UC). An increased risk of thrombosis in UC coupled with an observation that UC patients being treated with anticoagulant therapy for thrombotic events had an improvement in their bowel symptoms led to trials examining the use of unfractionated heparin (UFH) and low molecular weight heparins (LMWH) in (...) patients with active UC. OBJECTIVES: To review randomized trials examining the efficacy of unfractionated heparin (UFH) or low molecular weight heparins (LMWH) for remission induction in patients with ulcerative colitis. SEARCH STRATEGY: The MEDLINE (PUBMED), and EMBASE databases, The Cochrane Central Register of Controlled Trials, the Cochrane IBD/FBD group specialized trials register, review papers on ulcerative colitis, and references from identified papers were searched in an effort to identify all

Cochrane2008

184. Continuous heparin infusion to prevent thrombosis and catheter occlusion in neonates with peripherally placed percutaneous central venous catheters.

Continuous heparin infusion to prevent thrombosis and catheter occlusion in neonates with peripherally placed percutaneous central venous catheters. BACKGROUND: Complications associated with peripherally placed percutaneous central venous catheters (PCVC) in neonates include mechanical complications (catheter thrombosis, occlusion or dislodgement) and infection. Strategies to prevent catheter thrombosis and occlusion include the use of heparin. However, heparin is known to be associated (...) with complications such as bleeding and thrombocytopenia. OBJECTIVES: PRIMARY OBJECTIVE: To assess the effectiveness of heparin for prevention of catheter related thrombosis. SECONDARY OBJECTIVES: To assess the effectiveness of heparin on catheter occlusion, duration of catheter patency, catheter related sepsis and complications associated with the use of heparin. SEARCH STRATEGY: A literature search of MEDLINE, EMBASE, CINAHL from their inception to December 2007, The Cochrane Library (Issue 4, 2007

Cochrane2008

185. Differences between low-molecular-weight and unfractionated heparin for venous thromboembolism prevention following ischemic stroke: a metaanalysis

Differences between low-molecular-weight and unfractionated heparin for venous thromboembolism prevention following ischemic stroke: a metaanalysis Differences between low-molecular-weight and unfractionated heparin for venous thromboembolism prevention following ischemic stroke: a metaanalysis Differences between low-molecular-weight and unfractionated heparin for venous thromboembolism prevention following ischemic stroke: a metaanalysis Shorr A F, Jackson W L, Sherner J H, Moores L K CRD (...) summary This review found that low molecular weight heparins are associated with reduced risk of venous thromboembolism following ischaemic stroke, and no increased risk of bleeding compared with unfractionated heparin use. Overall this was a well-conducted review and the results appear to be reliable. Authors' objectives To compare low molecular weight heparin (LMWH) with unfractionated heparin (UFH) for the prevention of venous thromboembolism (VTE) following ischaemic cerebrovascular accidents (CVA

DARE.2008

186. Comparison of Tinzaparin and unfractionated heparin as anticoagulation on haemodialysis: equal safety, efficacy and economical parity

Comparison of Tinzaparin and unfractionated heparin as anticoagulation on haemodialysis: equal safety, efficacy and economical parity Comparison of Tinzaparin and unfractionated heparin as anticoagulation on haemodialysis: equal safety, efficacy and economical parity Comparison of Tinzaparin and unfractionated heparin as anticoagulation on haemodialysis: equal safety, efficacy and economical parity Bramham K, Varrier M, Asgari E, Makanjuola D Record Status This is a critical abstract (...) of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary The objective was to assess the costs and outcomes associated with the use of unfractionated heparin (UFH) and a low-molecular-weight heparin (LMWH, Tinzaparin TM ) for anticoagulation in patients on haemodialysis. The authors concluded

NHS Economic Evaluation Database.2008

187. Cost-effectiveness of dalteparin versus unfractionated heparin as venous thromboembolism prophylaxis in malignant gynecologic surgery

Cost-effectiveness of dalteparin versus unfractionated heparin as venous thromboembolism prophylaxis in malignant gynecologic surgery Cost-effectiveness of dalteparin versus unfractionated heparin as venous thromboembolism prophylaxis in malignant gynecologic surgery Cost-effectiveness of dalteparin versus unfractionated heparin as venous thromboembolism prophylaxis in malignant gynecologic surgery Wade WE, Spruill WJ Record Status This is a critical abstract of an economic evaluation (...) that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary The objective was to perform a cost-effectiveness analysis of dalteparin versus unfractionated heparin as prophylaxis for deep vein thrombosis or pulmonary embolism in patients who underwent surgery for gynaecologic malignancies. The authors preliminary

NHS Economic Evaluation Database.2008

189. Heparins reduce the number of heart attacks after acute coronary syndromes

Heparins reduce the number of heart attacks after acute coronary syndromes PEARLS Practical Evidence About Real Life Situations PEARLS are succinct summaries of Cochrane Systematic Reviews for primary care practitioners. They are funded by the New Zealand Guidelines Group. PEARLS provide guidance on whether a treatment is effective or ineffective. PEARLS are prepared as an educational resource and do not replace clinician judgement in the management of individual cases. View PEARLS online (...) at: www.cochraneprimarycare.org Heparins reduce the number of heart attacks after acute coronary syndromes Clinical question How effective are heparins in the treatment of patients with acute coronary syndromes (ACS)? Bottom line Compared to placebo, heparins reduce the number of heart attacks (NNT* 33) but cause more minor bleeding (NNH* 17) after ACS. The risks of mortality, revascularisation, recurrent angina, major bleeding and thrombocytopenia were similar in both groups. *NNT = number needed to treat to benefit one

Cochrane PEARLS2008

190. Low-molecular-weight heparin vs unfractionated heparin for perioperative thromboprophylaxis in patients with cancer: a systematic review and meta-analysis

Low-molecular-weight heparin vs unfractionated heparin for perioperative thromboprophylaxis in patients with cancer: a systematic review and meta-analysis Low-molecular-weight heparin vs unfractionated heparin for perioperative thromboprophylaxis in patients with cancer: a systematic review and meta-analysis Low-molecular-weight heparin vs unfractionated heparin for perioperative thromboprophylaxis in patients with cancer: a systematic review and meta-analysis Akl E A, Terrenato I, Barba M (...) , Sperati F, Sempos E V, Muti P, Cook D J, Schunemann H J CRD summary This review compared low-molecular-weight heparin and unfractionated heparin for prevention of death and adverse events caused by blood clots in cancer patients undergoing surgery. The authors found no evidence of a difference between the two treatments when administered before surgery. This was a generally well-conducted review and the conclusions were likely to be reliable. Authors' objectives To compare the benefits and harms

DARE.2008

191. Review: low-molecular-weight heparin prevented recurrent VTE more than oral anticoagulants in patients with cancer

Review: low-molecular-weight heparin prevented recurrent VTE more than oral anticoagulants in patients with cancer Review: low-molecular-weight heparin prevented recurrent VTE more than oral anticoagulants in patients with cancer | Evidence-Based Nursing This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in via your Society Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password (...) * your user name or password? Search for this keyword Search for this keyword Main menu Log in via your Society Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Review: low-molecular-weight heparin prevented recurrent VTE more than oral anticoagulants in patients with cancer Article Text Treatment Review: low-molecular-weight heparin prevented recurrent VTE more than oral anticoagulants

Evidence-Based Nursing (Requires free registration)2008

192. Bivalirudin versus unfractionated heparin during percutaneous coronary intervention.

Bivalirudin versus unfractionated heparin during percutaneous coronary intervention. 18703471 2008 08 15 2008 08 26 2016 11 24 1533-4406 359 7 2008 Aug 14 The New England journal of medicine N. Engl. J. Med. Bivalirudin versus unfractionated heparin during percutaneous coronary intervention. 688-96 10.1056/NEJMoa0802944 Whether bivalirudin is superior to unfractionated heparin in patients with stable or unstable angina who undergo percutaneous coronary intervention (PCI) after pretreatment with (...) clopidogrel is unknown. We enrolled 4570 patients with stable or unstable angina (with normal levels of troponin T and creatine kinase MB) who were undergoing PCI after pretreatment with a 600-mg dose of clopidogrel at least 2 hours before the procedure; 2289 patients were randomly assigned in a double-blind manner to receive bivalirudin, and 2281 to receive unfractionated heparin. The primary end point was the composite of death, myocardial infarction, urgent target-vessel revascularization due

NEJM2008

193. Heparin-bonded catheters for prolonging the patency of central venous catheters in children.

Heparin-bonded catheters for prolonging the patency of central venous catheters in children. BACKGROUND: Central venous catheters (CVCs) are a mainstay in the management of critically ill children. However, these catheters are associated with mechanical and infectious complications which reduce their life span. Heparin bonding of catheters has shown promise in animal studies and in adults. OBJECTIVES: The primary objective was to determine the effect of heparin-bonded CVCs on the duration (...) of catheter patency in children. Secondary objectives were to determine the effect of heparin-bonded catheters on catheter related thrombosis, occlusion, sepsis and side effects. SEARCH STRATEGY: We searched the Cochrane Peripheral Vascular Diseases (PVD) Group Trials Register (inception to August 2007) which contains trials identified through searches of MEDLINE (1966 to August 2007), EMBASE (1980 to August 2007), CINAHL (1982 to August 2007), and hand searches along with the Cochrane Central Register

Cochrane2007

196. Brief communication: Preoperative anticoagulant activity after bridging low-molecular-weight heparin for temporary interruption of warfarin.

Brief communication: Preoperative anticoagulant activity after bridging low-molecular-weight heparin for temporary interruption of warfarin. BACKGROUND: Preoperative low-molecular-weight heparin (LMWH) is often used when warfarin therapy is interrupted for surgery. OBJECTIVE: To determine the preoperative anticoagulant activity of LMWH following a standardized "bridging" regimen. DESIGN: Prospective cohort study. SETTING: Single university hospital. PATIENTS: Consecutive patients who had (...) warfarin therapy interrupted before an invasive procedure. INTERVENTION: Enoxaparin, 1 mg/kg of body weight, twice daily. The last dose was administered the evening before surgery. MEASUREMENTS: Blood anti-factor Xa heparin levels measured shortly before surgery. RESULTS: Preoperative anti-Xa heparin levels were obtained in 80 patients at an average of 14 hours after the last dose of enoxaparin was administered. The average anti-Xa heparin level was 0.6 U/mL. The anti-Xa heparin level, measured shortly

Annals of Internal Medicine2007

197. Meta-analysis: the utility and safety of heparin in the treatment of active ulcerative colitis

Meta-analysis: the utility and safety of heparin in the treatment of active ulcerative colitis Meta-analysis: the utility and safety of heparin in the treatment of active ulcerative colitis Meta-analysis: the utility and safety of heparin in the treatment of active ulcerative colitis Shen J, Ran Z H, Tong J L, Xiao S D CRD summary The review concluded that the administration of heparin in participants with ulcerative colitis is safe, but there is no additional benefit over conventional therapy (...) . Although the authors’ conclusions appear to follow from the data presented, clinical differences between the studies, particularly with regard to the specific treatment used, may affect their reliability. Authors' objectives To assess the efficacy and safety of heparin as a supplemental therapy, in comparison with conventional therapy, in patients with ulcerative colitis (UC). Searching MEDLINE (1966 to January 2007), EMBASE (1980 to January 2007), the Cochrane Controlled Trials Register (Issue 1, 2007

DARE.2007

198. Efficacy and safety of the low-molecular weight heparin enoxaparin compared with unfractionated heparin across the acute coronary syndrome spectrum: a meta-analysis

Efficacy and safety of the low-molecular weight heparin enoxaparin compared with unfractionated heparin across the acute coronary syndrome spectrum: a meta-analysis Efficacy and safety of the low-molecular weight heparin enoxaparin compared with unfractionated heparin across the acute coronary syndrome spectrum: a meta-analysis Efficacy and safety of the low-molecular weight heparin enoxaparin compared with unfractionated heparin across the acute coronary syndrome spectrum: a meta-analysis (...) Murphy S A, Gibson C M, Morrow D A, Van de Werf F, Menown I B, Goodman S G, Mahaffey K W, Cohen M, McCabe C H, Antman E M, Braunwald E CRD summary This review compared enoxaparin with unfractionated heparin in patients with acute coronary syndrome. The authors concluded that enoxaparin had a significant net clinical benefit, particularly for patients with ST-segment elevation myocardial infarction. The review had some methodological and reporting shortcomings, but included a number of very large

DARE.2007

199. Intravenous heparin in combination with antibiotics for the treatment of deep vein septic thrombophlebitis: a systematic review

Intravenous heparin in combination with antibiotics for the treatment of deep vein septic thrombophlebitis: a systematic review Intravenous heparin in combination with antibiotics for the treatment of deep vein septic thrombophlebitis: a systematic review Intravenous heparin in combination with antibiotics for the treatment of deep vein septic thrombophlebitis: a systematic review Falagas M E, Vardakas K Z, Athanasiou S CRD summary This review examined the effects of heparin for the treatment (...) of deep vein septic thrombosis. The authors tentatively concluded that the timely use of heparin with appropriate antibiotics may be beneficial. The overall reliability of this conclusion is uncertain, given the lack of controlled evidence and methodological weaknesses in the review process. Authors' objectives To examine the effects of heparin for the treatment of deep vein septic thrombosis. Searching PubMed, Current Contents and the Cochrane CENTRAL Register were searched for eligible studies

DARE.2007

200. Adjunctive benefits from low-molecular-weight heparins as compared to unfractionated heparin among patients with ST-segment elevation myocardial infarction treated with thrombolysis: a meta-analysis of the randomized trials

Adjunctive benefits from low-molecular-weight heparins as compared to unfractionated heparin among patients with ST-segment elevation myocardial infarction treated with thrombolysis: a meta-analysis of the randomized trials Adjunctive benefits from low-molecular-weight heparins as compared to unfractionated heparin among patients with ST-segment elevation myocardial infarction treated with thrombolysis: a meta-analysis of the randomized trials Adjunctive benefits from (...) low-molecular-weight heparins as compared to unfractionated heparin among patients with ST-segment elevation myocardial infarction treated with thrombolysis: a meta-analysis of the randomized trials De Luca G, Marino P CRD summary This review found that low molecular weight heparins are associated with a reduction in reinfarction and a trend towards reduced mortality, but with a higher risk of major bleeding complications, compared with unfractionated heparin. These conclusions are likely to be reliable, but should

DARE.2007